Loading company…
Jerusalem biotech developing RNA-based antisense oligonucleotide therapies for cystic fibrosis and other serious lung diseases.
Founded in 2016 and headquartered in Jerusalem, Israel, Splisense Ltd. develops RNA-based therapies using antisense oligonucleotides (ASOs) for serious pulmonary diseases, including cystic fibrosis and idiopathic pulmonary fibrosis. Its technology builds on research by Professor Batsheva Kerem of the Hebrew University, and its lead product targets a specific CFTR mutation. The company raised USD 28.5 mn in a Series B round led by the Cystic Fibrosis Foundation on May 13, 2021, and Gili Hart is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in